Psychiatric aspects of Parkinson's disease

Current Opinion in Psychiatry
Uwe Ehrt, Dag Aarsland

Abstract

Recently, there has been much interest and rapid progress in understanding the neuropsychiatry of Parkinson's disease. This paper reviews the most important papers published during 2004 on dementia and cognitive impairment, depression and psychosis in Parkinson's disease. Many new studies of cognitive impairment and dementia in Parkinson's disease have been published during 2004. Cognitive impairment has been demonstrated even during the first 1-2 years after onset of disease. Whereas executive and attentional impairment is typical, learning deficits occur early in some patients. Both functional and structural imaging suggest that in addition to fronto-subcortical deficits, temporal and parietal changes occur early as well. In the first large placebo-controlled trial, the cholinesterase inhibitor rivastigmine improved cognition, daily functioning and psychiatric symptoms without worsening of parkinsonism. The frequency and characteristics of depression, anxiety and hallucinations have been explored in several studies. Unfortunately, there is still little scientific evidence available to guide the treatment of these important aspects of Parkinson's disease, and adequately designed clinical trials are needed. Although subthalamic...Continue Reading

References

Feb 1, 1996·Archives of Neurology·E TandbergJ L Cummings
Jan 1, 1997·Journal of Neurology·B Dubois, B Pillon
May 5, 1998·Neurology·F J Jiménez-JiménezJ A Molina
Mar 29, 2001·Neurology·D AarslandP Kragh-Sørensen
Feb 9, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Giovanni Defazio, Paolo Livrea
Mar 29, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzUNKNOWN Parkinson Study Group
Sep 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Katrina Gwinn-Hardy
Sep 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Sujana ReddyPaul J Feustel
Nov 16, 2002·Archives of Neurology·Michael S OkunMahlon R DeLong
Dec 11, 2002·Neurology·C G BallardM Tovee
Feb 14, 2003·Dementia and Geriatric Cognitive Disorders·Carmen JanvinKenneth Hugdahl
Jun 11, 2003·Neurology·S A FactorUNKNOWN Parkinson Study Group
Jun 20, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Hubert H FernandezJoseph H Friedman
Jun 20, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Richard CamicioliJeffrey A Kaye
Jun 26, 2003·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·I RektorováJ Velísková
Jul 10, 2003·Lancet Neurology·Murat Emre
Dec 4, 2003·Neuropsychologia·Kathy DujardinAlain Destée
Dec 24, 2003·Brain : a Journal of Neurology·Thomas FoltynieRoger A Barker
Dec 25, 2003·Lancet Neurology·Ian McKeithUNKNOWN International Psychogeriatric Association Expert Meeting on DLB
Jan 13, 2004·International Journal of Geriatric Psychiatry·Iracema LeroiLaura Marsh
Feb 3, 2004·The American Journal of Psychiatry·Carlos Schönfeldt-Lecuona, Bernhard J Connemann
Mar 3, 2004·The Journal of Neuropsychiatry and Clinical Neurosciences·Edward C LauterbachRobert L Vogel
Mar 11, 2004·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·C E MorrisonC W Olanow
Apr 17, 2004·Journal of the American Geriatrics Society·Daniel WeintraubMatthew B Stern
Apr 20, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·P PollakI Bourdeix
Apr 20, 2004·Clinical Neuropharmacology·Hubert H FernandezJoseph H Friedman
May 4, 2004·Parkinsonism & Related Disorders·Sari LaatuJuha O Rinne
May 15, 2004·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A NutiU Bonuccelli
May 18, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·A FunkiewiezP Pollak
Jun 18, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·R Tomer, J Aharon-Peretz
Jun 23, 2004·Archives of Gerontology and Geriatrics. Supplement·E SinforianiG Sandrini
Jun 24, 2004·Archives of Neurology·Padraig E O'SuilleabhainRamon Diaz-Arrastia
Jul 10, 2004·Acta Neurologica Scandinavica·T A HughesE G S Spokes
Jul 15, 2004·Clinical Neuropharmacology·Valerie Voon, Anthony E Lang
Jul 16, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Hubert H FernandezJoseph H Friedman
Aug 18, 2004·Journal of Geriatric Psychiatry and Neurology·Albert F G Leentjens
Aug 18, 2004·Journal of Geriatric Psychiatry and Neurology·Dag AarslandGlenda Halliday

❮ Previous
Next ❯

Citations

Jun 6, 2008·Social Science & Medicine·Caroline WilliamsonCraig D Murray
Feb 16, 2008·Suicide & Life-threatening Behavior·Carmelle PeisahMichael Rodriguez
Jan 24, 2008·International Journal of Geriatric Psychiatry·Cindy W C TamW M Chan
Sep 7, 2012·Australasian Journal on Ageing·Sallyanne AaronsChanaka Wijeratne
Feb 27, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G Goetz
May 7, 2011·Journal of Geriatric Psychiatry and Neurology·Jan MohlmanBianca Georgescu
Jun 13, 2012·Physiology·Alexxai V Kravitz, Anatol C Kreitzer

❮ Previous
Next ❯

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.